Directory
Portfolio companies.
34,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
143
currently held
Exits tracked
27
hand-checked
Sectors covered
1
across the portfolio
Countries covered
1
from every market
Latest activity
Caledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capital
Elaia PartnersadminCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway2 weeks agoCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway
adminLauxera Capital PartnersadminBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board1 month agoBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board
admin162 companies matching · Page 4 of 4
| Company | Sector | Geo | Investor | Entry | Hold | Status | Buyer | MOIC | |
|---|---|---|---|---|---|---|---|---|---|
Hornet Therapeutics 4BIO Ventures III | 4Bio Partners | 2024 | 2yr | Active | – | – | |||
Mariposa Therapeutics Development Bank of Wales (Balance Sheet) | Development Bank of Wales | 2026 | 0yr | Active | – | – | |||
MeOmics Precision Medicine Development Bank of Wales (Balance Sheet) | Development Bank of Wales | 2026 | 0yr | Active | – | – | |||
Mogrify Parkwalk Opportunities EIS Fund | Parkwalk Advisors | 2021 | 5yr | Active | – | – | |||
Oxford Cancer Analytics Eka Ventures Fund I | EKA Ventures | 2022 | 4yr | Active | – | – | |||
Promatix ALSA Ventures European Biotechnology Fund | ALSA Ventures | 2021 | 5yr | Active | – | – | |||
PsiOxus Therapeutics Rosetta Capital V | Rosetta Capital | 2021 | 5yr | Active | – | – | |||
Re-Vana Therapeutics Ltd QUBIS Ltd | Qubis | 2016 | 10yr | Active | – | – | |||
ReNewVax QUBIS Ltd | Qubis | 2025 | 1yr | Active | – | – | |||
Sable Bio MMC Ventures EIS Fund | MMC Ventures | 2025 | 1yr | Active | – | – | |||
Sensible Biotechnologies BlueYard Capital Fund III | BlueYard Capital | 2023 | 3yr | Active | – | – | |||
Thelior Bio Oxford Science Enterprises Balance Sheet | Oxford Science Enterprises | 2025 | 1yr | Active | – | – |
Hornet Therapeutics
4BIO Ventures III
UKSector
Biotech
Investor4Bio Partners
Entry
2024
Hold
2yr
Mariposa Therapeutics
Development Bank of Wales (Balance Sheet)
UKSector
Biotech
InvestorDevelopment Bank of Wales
Entry
2026
Hold
0yr
MeOmics Precision Medicine
Development Bank of Wales (Balance Sheet)
UKSector
Biotech
InvestorDevelopment Bank of Wales
Entry
2026
Hold
0yr
Mogrify
Parkwalk Opportunities EIS Fund
UKSector
Biotech
InvestorParkwalk Advisors
Entry
2021
Hold
5yr
Oxford Cancer Analytics
Eka Ventures Fund I
UKSector
Biotech
InvestorEKA Ventures
Entry
2022
Hold
4yr
Promatix
ALSA Ventures European Biotechnology Fund
UKSector
Biotech
InvestorALSA Ventures
Entry
2021
Hold
5yr
PsiOxus Therapeutics
Rosetta Capital V
UKSector
Biotech
InvestorRosetta Capital
Entry
2021
Hold
5yr
Re-Vana Therapeutics Ltd
QUBIS Ltd
UKSector
Biotech
InvestorQubis
Entry
2016
Hold
10yr
ReNewVax
QUBIS Ltd
UKSector
Biotech
InvestorQubis
Entry
2025
Hold
1yr
Sable Bio
MMC Ventures EIS Fund
UKSector
Biotech
InvestorMMC Ventures
Entry
2025
Hold
1yr
Sensible Biotechnologies
BlueYard Capital Fund III
UKSector
Biotech
InvestorBlueYard Capital
Entry
2023
Hold
3yr
Thelior Bio
Oxford Science Enterprises Balance Sheet
UKSector
Biotech
InvestorOxford Science Enterprises
Entry
2025
Hold
1yr